Replies to post #100652 on Amarin Corp Plc (AMRN)

[HDGabor]

V-

Fully agree (especially: "study patients are using the planned study visits as free ongoing cardiac care and may no be seeing their regular cardiologists intensively during the study")

and V isn't available for app. 60% of patients in the study (ex-US sites).

Before P- come up with L / gL idea: the chance that a patient - who cares his / her lipids - choose a trial (with a 50% chance to be in a placebo arm and 50% chance to be in the unproved treatment arm) instead of L / gL treatment, but based on lipid result leave the study and start to take L / gL ... is minimal (or nil).

Best,
G

[Whalatane]

VU Interesting post. Have U looked at

theheart.org on Medscape
The Primary Endpoint Is Positive: What More Do You Need?
Gregg W. Stone, MD ...2017

Probably must reading for anyone seriously discussing R-IT

Consider your pts re previous trials . The world does not stand still :-)
Look at the use of drug eluting stents , long term duel antiplatelet therapy ..low dose aspirin daily plus clopidogrel ...DAPT trial ...

In conclusion, among patients treated with drug-eluting stents, continuation of thienopyridine-plus-aspirin therapy, as compared with aspirin therapy alone, beyond 1 year reduced the risks of ischemic events.
-------------------
So in the R-IT population you now have more use of drug eluting stents and longer treatment with low dose aspirin and clopidogrel

My pt ..IMHO those in R-IT , at least in the US are benefitting from incremental improvements in risk reduction ...developed and implemented since R-IT was designed .


Therefore the placebo rate will be lower then what most on this board expect it to be .
JMO
Kiwi